Generic/TRADE Class / Pregnancy Category 9 Side Effects

Total Page:16

File Type:pdf, Size:1020Kb

Generic/TRADE Class / Pregnancy Category 9 Side Effects Erectile Dysfunction Comparison Chart (ED) Treatment Chart 1,2,3,4,5,6,7,8 Canadian 2006 S Downey, B Jensen, L Regier © www.RxFiles.ca June 10 Generic/TRADE Class / Side effects / Contraindications CI √ = therapeutic use / Comments / INITIAL;MAX; $ (Strength & forms) Pregnancy category 9 Drug Interactions DI / Monitor M USUAL DOSE 8 doses 10% 4% 2% √idiopathic, postencephalitic, symptomatic (Option: SSRI induced ED) Sildenafil Oral selective Common: flushing , diarrhea , dizziness , S 25-50mgÆ $99-102 V,S,T V,S >10% <8% (Onset similar: generally 30-60min ; as early as 10-15min ); S&T: pulmonary arterial HTN. VIAGRA =S phosphodiesterase-5 headache ,dyspepsia , blurry vision (visual 100mg x1/24h $109 35 25, 50, 100mg tab χ⊗ PDE5 inhibitor: disturbance > with S,V), myalgia (T=6% ), nasal Peak effect: S &V ~1hr; T ~2hr; Duration: S&V~4-12hr T ≤ 36hr 50-100mg, 10,11,12,13,14 ; approved 1999 congestion & rash 2% esp S ; GI upset dose-related & DI: ↑ hypotension: α-1 blockers (especially in new pt; avoid or space by >4hrs); 30-60min pre-sex -reduce catabolism of ⊗≥ (>10% at dose high (Revatio ), nitrates (CI or caution); antihypertensives (esp. vasodilators) & alcohol 20-80mg tab tid $1050 cGMP resulting in smooth visual disturbance ?(↓smell, →PAH) see QT chart p.17 T 5-10mgÆ $125 per month,new:USAIVform Nitrate washout period V amnesia,hearing loss). [hot flashes if used in ] : S & V~24hr; T ~48hr. :QT muscle relaxation of the ↑ levels of PDE5 by: CYP 3A4 inhibitors (azole antifungals, cimetidine, cipro, erythromycin/ 20mg x1/24h $122 Tadalafil corpus cavernosum and Serious: rare MI & *priapism; QT prolongation –V, juice inhibitors 23 cell crisis macrolides, tacrolimus), doxycycline, grapefruit , isoniazid, protease , 10-20mg 1-2hr very rare cases of NAION ,?seizures, ?sickle Max interval q24h Max interval q72h ↑ blood flow into penis CIALIS =T quinidine, verapamil. (PDE5:use lowest dose; S,V: T: ) pre-sex carbamazepine, phenytoin, phenobarb, rifampin 15,16 (need sexual stimulation to CI: nitrates: ↑↑ hypotensive effect & ↑↑ heart rate 2.5,5,10,20mg tab χ⊗ 31 ↓ effect: enzyme inducers ; ↓S&T by bosentan. 2.5-5mg daily 30days option $132 (Adcirca χ ⊗ produce actual erection) (AVOID within 24h of S,V; 48h of T ); 20-40mgtabod FDA’09; high fat meals may delay and reduce efficacy of S & V. S >25mg ,T,V α-1 blockers (if new pt or if given ≤ 4hrs) glucose, lipid, TSH, testosterone USA is IV form→PAH) -considered FIRST LINE M:S,T= liver & renal fx, V=liver fx tests (Initial workup usually: ) Precautions: anatomical penis deformation; CV dx Vardenafil unless CI, but ~30% of men Dose Adjustments: >65years old: initial; S=25 mg T= by CrCl V=5mg V 5-10mgÆ $102-111 may still not respond to (eg. arrhythmia,recent MI/stroke,uncontrolled HTN, Liver dx: Initial S=25 mg, T=10mg V=5mg 20mg x1 /24h $119 LEVITRA =V PDE5’s monotherapy. coronary ischemia, HF); ↑ risk of priapism* (eg, Renal dx CrCl <30mL/min: Initial S=25 mg T=5mg V= no adjustment 10-20mg, 5,10, 20mg tab χ⊗ sickle cell anemia, multiple myeloma, or leukemia); Daily or 3x/week dosing may be more efficacious for poor responders 36 30-60min pre-sex 17,18,19,20,21,22,23,24,25,26 27 36 B liver dx; multi BP meds; ↓ renal fx; NAION ; < 5% of Non-responders will respond to a different PDE-5 inhibitor Frequently as adulterants in herbs: Acai Berry products, Actra-Sx,STDs; Adam retinitisFree, Armstong pigmentosa/ Natural, Aspire36retinal & Aspire abnormalities LIte, Aspire T preferred Lite,. Axcil, 4Everon, Actra-Rx, Blue Steel, China Vigour, Chong Cao Ju Wang , Chongcaoliubian Jiaonang, Darling Caps, Dali Caps, Deguozhanjiang, Deguozonghengtianxia, Desirin, Dr. Life, Ehanix New Extra Men's Formula, Encore tabs for Men, Energy Max, Erextra, Excite, Firm Dose, Granite Rooster, Herb Vigour, Hero, HS Joy of Love, Jia Yi Jian, Jolex, Jiu Bian Wang, Kang Da, King Power Oral Soln, Lady Shangai, Libidfit, Libidus, Libimax, Libipower Plus, Liviro3, Max V& Rhino, Lover Liquid Nutriment, Lu Quan, Meng Rong, Nangen Zengzhangsu, Nasutra, Naturalë Super Plus, NaturalUp, Natural Vigour, Neophase,Once More, Onyo, Oyster Plus, Platinum Power 58 Extra, Power 58, Power 1 Walnut, Powertabs, Power Up, Santi Scalper Penis Erection, Rize 2 The Occasion Caps, Rockhard Weekend, Rose 4 Her Capsules, Sanbianwan,Satis 60hr Ever Lasting, Shangai Regular & Ultra & X, Spanish Fly ,Stamina Rx, Steam, Stiff Nights, Stretch Up, Strong Testis, Super Shangai, Super X, Sweet Energizer Vitality, Tian Li, Tian Huang Gu Shen Dan, Top Gun for Men Herbal Extracts,True Man, Ultimates, Urat Madu, Valentino, for men Vigoureux, VG, Vigor-25, Vigorect, Viril-ity Power vpxl No1, Yilishen, Yixinjiaonang, Xiadafil VIP, XOX , XP Tongkat Ali Supreme, Viapro, Viril-Ity -Power, Wodibo, Zencore & Plus, Zhong Guo Shen Fang , Zhong Hua Niu Bian, Zhuang Yao Gu Shen, Zhuang Tjar Gere, Zui Xian Dan Gon g Shi Z, Zimaxx etc.. Ch C Neurogenic ED: Alprostadil χ⊗ 7% 14% √ vasculogenic, psychogenic, neurogenic & mixed $248 Prostaglandin E Common: ↓ HR , dizziness, fever , headache, Titrate from 1 ug CAVERJECT, 4% 37% 3% Onset = rapid Duration= <1hr 10 doses -activates cAMP which hypotension , penile pain , penile fibrosis , Usual: 2-5ug 20 ug vial (powder) 3% CAVERJECT tachycardia , urethral burning, vaginal itch (in Initial dosage/titration should occur under medical supervision (due to risk of Vascular ED: intracavernosal inj. relaxes smooth muscle and partner with transurethral systems) syncope). Pts receiving intracavernosal inj should be assessed by Dr. q12months Titrate from 4ug produces vasodilation 28 33 MUSE 4% <4% Vascular ED requires larger doses (>20ug) vs neurogenic ED (2-5ug) Usual: 5-20ug (also inhibition of platelet Serious: seizures , priapism* , HF, second degree 250, 500, 1000 ug Injection: no more than 3 doses/week (with 24 hours between doses) Severe: 40-60ug $200 aggregation and gastric heart block, supraventricular tachycardia, ventricular Inject 10-30mins urethral supp <1% Suppositories: no more than 2 within 24 hours 8 doses secretion, stimulation of fibrillation , disseminated intravascular pre-sex (refrigerate; otherwise 1% MUSE intestinal smooth muscle, coagulation & cortical proliferation of long bones ↓ dose if erection lasts greater than one hour with either system 125-250ug; 14days at RT) 29,30,31 uterine smooth muscle) CI: anatomical penis deformation, penile implant, 1000ug x1/24h Seek medical assistance if tx results in erection that lasts >4 hr. $55-85 Prostaglandin χ⊗ predisposition to priapism* (sickle cell anemia or trait, DI: heparin (↑ partial thromboplastin time & thrombin time); ↑ risk of 250-500ug -most efficacious of pre-sex 32 leukemia, myeloma), Peyronie's disease symptomatic hypotension, syncope with vasodilators, antihypertensives, alcohol 10-30mins 5ml vial E1 (PGE1) = E1 injectable agents Precautions: concurrent anticoagulant, vasoactive (dose depends on 0.5-1ml/dose inj corpora cavernosa; X M: *priapism (erection lasting >4hr) tx=needle aspiration of penile blood; agents or bleeding abnormalities venous anatomy compounded transurethral gel intracavernosal inj phenyleprhine 200ug q5min up to 500ug if needed) 34 not ED etiology) Common: abdominal discomfort, anorexia, Papaverine = Pv Vasodilator √ idiopathic, postencephalitic & symptomatic (not FDA indication) 30 mg constipation, diarrhea, nausea, vomiting, 30mg/ml inj. soln (non-selective PDE 2,3,4 Papaverine in any ischemic type condition is not recommended. $40 drowsiness, headache, vertigo, hypertension, 60mg (2ml vials) χ⊗ inhibitor) Do not use more than 3 times weekly or 2 days in succession. 30mg-60mg 10x2ml tachycardia, pruritis, rash & blurred vision? Combos: -0.5-1 mg phentolamine intracavernosal; -produces generalized intracavernosal vials Serious: acidosis, ↑intercranial pressure, phentolamine & alprostadil by intracavernosal inj arteriolar dilation & over 1-2 min smooth muscle relaxation hepatotoxicity & priapism* Consult Dr. if erection lasts more than 4 hours after self inj -can be combined with CI: complete atrioventricular block T½= 0.5-2hr Compounded Products Precautions: glaucoma, liver dx, recent MI, stroke, prostaglandin &/or C DI: levodopa (↓ levodopa affect), ginkgo (↑ SE of papaverine) Bi-mix inj = Pt + Pv phentolamine Parkinsonism & sickle cell anemia M: intraocular pressure in glaucoma patients, liver fx 6ml vial = $60 3% Phentolamine χ⊗ Alpha-Adrenergic Common: chest pain, diarrhea, dizziness , √ idiopathic, postencephalitic & symptomatic (not FDA indication) 0.5-1ml/dose 3% 2% 10% = Pt Blocker headache , hypotension , nasal congestion , Take one hour prior to sexual activity Tri-Mix inj =Pt + Pv + E1 nausea, palpitations1%, ↑HR1-7% & vomiting in 3 strengths -antagonizes anti-erectile Peak activity: 30-60min Onset of action: 30-40min Duration: 5-7hr Rogitine, generic Serious: arrhythmia $60-80 per 5ml vial 5mg lypholized sympathetic tone, ↑perfusion Compounded mixes may ↑ efficacy and ↓ pain associated with prostaglandin CI: myocardial infarction, CAD, angina pectoris, 0.2-1ml per dose powder for injection - poor efficacy alone so DI: ↑ hypotension: beta blockers, tadalafil & vardenafil; disulfiram like rx with hypersensitivity to phentolamine or mannitol, renal TriMix also available in usually combined with impairment, coronary or cerebral arteriosclerosis alcohol; ↓ effect with ephedrine (OTC cough/cold products, diet & “wake-up” pills) Transurethral gel As adulterants in: prostaglandin &/or Desire Precautions: arrhythmia, cerebral vascular spasm M: blood pressure changes, heart rate $40-120 / 5x1ml syr papaverine C or occlusion,
Recommended publications
  • Development and Validation of a UHPLC-UV Method for The
    Development and validation of a UHPLC-UV method for the detection and quantification of erectile dysfunction drugs and some of their analogues found in counterfeit medicines. Pierre-Yves Sacré a,b, Eric Deconinck a, Patrice Chiap c, Jacques Crommen b, François Mansion b, Eric Rozet d, Patricia Courselle a, Jacques O. De Beer a,* a Laboratory of Drug Analysis, Scientific Institute of Public Health, Brussels, Belgium b Department of Analytical Pharmaceutical Chemistry, Institute of Pharmacy, University of Liège, Liège, Belgium. c Advanced Technology Corporation (A.T.C.), University Hospital of Liège, Liège, Belgium d Department of Analytical Chemistry, Institute of Pharmacy, University of Liège, Liège, Belgium. Abstract Pharmaceutical counterfeiting is a permanently growing problem. Control laboratories are constantly analysing counterfeit medicines. In industrialised countries, one of the main counterfeited class of medicines are erectile dysfunction drugs. This paper describes the development and validation of a fast method to detect and quantify the three authorised phosphodiesterase type 5 inhibitors and five analogues. The method is based on the use of a sub-2 microns polar-embedded column with a gradient using acetonitrile as organic modifier and 10 mM ammonium formate buffer (pH 3.5) as aqueous component of the mobile phase. The separation was achieved in less than 4.5 min. The method has also been compared to the registered HPLC method for the assay of Viagra ® which was considered as the reference method. The method is also compatible with on-line coupling mass spectrometry and will significantly reduce analysis times and solvent consumption. Keywords: Phosphodiesterase type 5 inhibitors; UHPLC; method validation, analogues, counterfeit drugs, accuracy profiles.
    [Show full text]
  • ED Analogues Analysis
    UPLC-MS/MS for the Screening, Confirmation and Quantification of 32 Drugs illegally added to Herbal/Dietary Supplements for the Enhancement of Male Sexual Performance 1Salman Azimi*, 2Nayan Mistry and 2Michelle Wood 1Drug Quality Control Laboratory, Pharmacy & Drug Control Dept., Supreme Council of Health, PO Box 1919, Doha - Qatar. 2 Figure-5: Photographs of six positive samples. Forty-three suspected Waters Corporation, Atlas Park, Wythenshawe, Manchester, M22 5PP, UK. samples were analyzed in this study; 18 were found to be adulterated with ED drugs. ABSTRACT RESULTS & DISCUSSION The adulteration of herbal/dietary supplements with erectile dysfunction (ED) drugs and their analogues is reported For the purpose of screening , a spectral library for known ED drugs and analogues was prepared. Owing to recent reports Table 2: List of 32 compounds with retention times, and optimised MRM transitions parameters. Table-3: Summary of results for eight adulterated herbal/dietary samples. The screening results, including spectral match worldwide and is an increasing problem[1]. The sale of so-called 100%, ‘all-natural’ products has become a highly of increased availability of ‘all-in-one’/ ‘combination’ herbal products[2], we also added the naturally-occurring substances factors, RT data and final screening status ( = positive or - = negative) are presented, in addition to the quantitative data Retention Precursor Cone Quantifier Qualifier %CV (n=4) from the subsequent confirmatory analysis. profitable business for online pharmacies, however these products can pose a serious threat to consumers owing to the Icariin and yohimbine, the synthetic, dapoxetine (used for premature ejaculation) and testosterone. The library was CE CE Dwell LOQ undisclosed presence of approved/prescription drugs or the unknown safety and toxicity profile of unapproved ED drugs.
    [Show full text]
  • Tainted Products Marketed As Dietary Supplements
    Tainted Products Marketed as Dietary Supplements Jason Humbert, MPS Nicole Kornspan, MPH Regulatory Operations Officer Consumer Safety Officer Food and Drug Administration Office of Regulatory Affairs Health Fraud Branch Overview • Definition of health fraud • Tainted products – then and now • Dietary Supplement Health and Education Act of 1994 (DSHEA) • Concerns related to tainted products • Enforcement challenges • Resources 2 FDA Definition of Health Fraud • The deceptive promotion, advertisement, or sale of products as being effective to diagnose, prevent, cure, treat, or mitigate disease, or to provide a beneficial effect on health, but which have not been scientifically proven safe and effective for such purposes. • May be deliberate, or done without adequate knowledge or understanding of the product. 3 Health Fraud: What are the Risks? • Direct health hazard: product is likely to cause injury, death or other serious adverse effect when used as directed • Indirect health hazard: product poses no direct hazard, but consumer is likely to delay or discontinue appropriate medical treatment by relying on product. 4 4 Tainted Products – Then • 1865-1906: “Golden age” of American quackery • 1905 estimate: 50,000 patent medicines – Drugs were bought and sold like any other consumer good. – Contain dangerous, addictive, misidentified ingredients – Alcohol, cocaine, heroin, opium, without restrictions – Did not have to disclose ingredients – No warnings about misuse – Manufacturer not listed 5 Tainted Products – Now 6 6 Dietary Supplement
    [Show full text]
  • Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry
    molecules Article Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry 1,2, 1,3, 4 5 3 Unyong Kim y, Hyun-Deok Cho y, Myung Hee Kang , Joon Hyuk Suh , Han Young Eom , Junghyun Kim 6, Sumin Seo 1, Gunwoo Kim 1, Hye Ryoung Koo 1, Nary Ha 1, Un Tak Song 1 and Sang Beom Han 1,* 1 Department of Pharmaceutical Analysis, College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Korea; [email protected] (U.K.); [email protected] (H.-D.C.); [email protected] (S.S.); [email protected] (G.K.); [email protected] (H.R.K); [email protected] (N.H.); [email protected] (U.T.S.) 2 Biocomplete Co., Ltd., 272 Digital-ro, Guro-gu, Seoul 08389, Korea 3 Bioanalysis and Pharmacokinetics Study Group, Korea Institute of Toxicology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea; [email protected] 4 Agro-Livestock and Fishery Products Division, Busan Regional Korea Food and Drug Administration, 222 Geoje-daero, Yunje-gu, Busan 47537, Korea; [email protected] 5 Department of Food Science and Human Nutrition, Citrus Research and Education Center, University of Florida, 700 Experiment Station Rd, Lake Alfred, FL 33850, USA; joonhyuksuh@ufl.edu 6 Forensic Toxicology Division, National Forensic Service, 10 Ipchoon-ro, Wonju, Gangwon-do 26460, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-820-5596 These authors contributed equally to this work. y Received: 22 May 2020; Accepted: 9 June 2020; Published: 12 June 2020 Abstract: An accurate and reliable method based on ion trap–time of flight mass spectrometry (IT–TOF MS) was developed for screening phosphodiesterase-5 inhibitors, including sildenafil, vardenafil, and tadalafil, and their analogs in dietary supplements.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • 2251 Adulteration of Dietary Supplements with Drugs
    BRIEFING 2251 Adulteration of Dietary Supplements with Drugs and Drug Analogs. This new general chapter provides tools for detection of dietary supplement adulteration with ⟨extraneously⟩ added synthetic compounds. The illegal addition of synthetic substances to products marketed as dietary supplements constitutes a significant threat to consumer health, considering that these products, administered without medical supervision, may contain toxic constituents or substances whose safety has never been examined, and whose interaction with medications may be unpredictable or lethal. The proposed chapter suggests multiple methods for detection of adulteration. It is advisable to use several screening techniques to maximize the potential for adulteration detection, because no single methodology is universally applicable. Presently, the chapter targets supplements adulterated with phosphodiesterase type 5 inhibitors; subsequent revisions will include methodologies specific to analysis of adulterated weight loss and sports performance enhancement products. It is anticipated that this chapter will be updated regularly. (GCCA: A. Bzhelyansky.) Correspondence Number—C144928 Add the following: ▪ 2251 ADULTERATION OF DIETARY SUPPLEMENTS WITH DRUGS AND DRUG ANALOGS ⟨ ⟩ INTRODUCTION The illegal addition of undeclared synthetic compounds to products marketed as dietary supplements1 (DS) is a serious problem. This fraud is practiced to impart therapeutic effects that cannot be achieved by the supplement constituents alone. Increasingly, synthetic intermediates and structural analogs of the pharmaceuticals and drugs that have been discontinued or withdrawn from the market due to unsatisfactory safety profiles are being used as adulterants. Multiple adulterating compounds may be added to a single DS, frequently in erratic amounts. The proposed test methodologies facilitate screening of DS for synthetic adulterants. No individual technique is capable of addressing all potential analytes; thus, a combination of orthogonal approaches adds certainty to the analytical outcome.
    [Show full text]
  • Vardenafil Better Choice for Premature Ejaculation
    August 15, 2005 • www.familypracticenews.com Men’s Health 47 Vardenafil Better Choice for Premature Ejaculation BY ROBERT FINN (24%) of the men and was secondary (in On a self-rating scale of 0-8, where 0 Center but is now at the University of San Francisco Bureau most cases to erectile dysfunction) in the means PE almost never, 4 means PE about Hamburg. remaining 26 men (77%). half the time, and 8 means PE almost al- Self-ratings of sexual satisfaction, on a 0- S AN A NTONIO — Vardenafil improved After a 4-week run-in period, 17 men ways, the mean score was 6.14 at baseline, 5 scale, where 0 means not at all satisfied premature ejaculation more than sertra- were given 10-mg vardenafil 10 minutes 4.28 with sertraline, and 3.2 with varde- and 5 means extremely satisfied, averaged line, Frank Sommer, M.D., reported at the before intercourse for 6 weeks. The other nafil. 1.4 at baseline, 3.2 with sertraline, and 4.2 annual meeting of the American Urolog- 17 received 50 mg of sertraline 4 hours be- IVELT, as measured by a stopwatch, with vardenafil. In addition, the partners’ ical Association. fore intercourse. averaged 0.54 minutes at baseline, 2.87 sexual satisfaction showed significant in- Both vardenafil (Levitra), a phosphodi- After a 1-week washout period, the men minutes with sertraline, and 5.23 minutes creases for sertraline and even more so for esterase-5 inhibitor, and sertraline (Zoloft), who had been receiving sertraline with vardenafil, reported Dr. Sommer, vardenafil.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,675,619 B2 Fossel (45) Date of Patent: *Jun
    USOO9675619B2 (12) United States Patent (10) Patent No.: US 9,675,619 B2 FOSSel (45) Date of Patent: *Jun. 13, 2017 (54) TREATMENT OF ERECTILE DYSFUNCTION 31/198 (2013.01); A61K 31/495 (2013.01); AND OTHER INDICATIONS A6 IK3I/4985 (2013.01); A61K 3 1/506 (2013.01); A61 K3I/519 (2013.01); A61 K (71) Applicant: Strategic Science & Technologies, 47/02 (2013.01); A61K 47/06 (2013.01); A61 K LLC, Cambridge, MA (US) 47/10 (2013.01); A61K 47/12 (2013.01); A61 K 47/14 (2013.01); A61K 47/16 (2013.01); A61 K (72) Inventor: Eric T. Fossel, Cambridge, MA (US) 47/183 (2013.01); A61K 4 7/22 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01) (73) Assignee: Strategic Science & Technologies, (58) Field of Classification Search LLC, Cambridge, MA (US) CPC .............. A61K 2300/00; A61K 31/198; A61 K (*) Notice: Subject to any disclaimer, the term of this 31/.495; A61K 3 1/506; A61K 31/519; patent is extended or adjusted under 35 A61K 3 1/53: A61K 9/0014; A61 K U.S.C. 154(b) by 0 days. 31/4985; A61K 47/02: A61K 47/10; A61K 47/16; A61K 47/183: A61K 47/22: This patent is Subject to a terminal dis A61K 47/26: A61K 47/06; A61K 47/12: claimer. A61K 47/14: A61K 47/36; A61K 9/0034; A61K 9/06; A61K 9/107 (21) Appl. No.: 15/290,504 USPC ............................................................ 424/45 See application file for complete search history. (22) Filed: Oct.
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Development of Un-Targeted Screening Method for Detection of Synthetic PDE-5 Inhibitors and Analogues Adulterated in Health Supplements on LCMS-IT-TOF
    PO-CON1538E Development of Un-targeted Screening Method for Detection of Synthetic PDE-5 Inhibitors and Analogues Adulterated in Health Supplements on LCMS-IT-TOF ASMS 2015 TP102 Jie Xing1, Dinash Aravind2, Zhe Sun1, Ang May Yen3 and Zhaoqi Zhan1 1 Shimadzu (Asia Pacic) Pte Ltd, 79 Science Park Drive #02-01/08, Singapore 118264, 2 National Pharmaceutical Control Bureau, Jalan Universiti, 46200 PetalingJaya, Selangor, Malaysia, 3 Shimadzu Malaysia SdnBhd, Kota Damansara, 47810 PetalingJaya, Selangor, Malaysia Development of Un-targeted Screening Method for Detection of Synthetic PDE-5 Inhibitors and Analogues Adulterated in Health Supplements on LCMS-IT-TOF Introduction Sildenal and other synthetic phosphodiesterase type 5 LC/MS/MS [1-3] are used for detection of targeted PDE-5 enzyme (PDE-5) inhibitors are used for treatment of erectile inhibitors, but it is challenging to detect unknown dysfunction (ED) in men. Sildenal, tadalal, vardenal, adulterants in actual samples. We present here a novel avanal and udenal are the approved PDE-5 drugs in un-targeted screening method using LCMS-IT-TOF and a different countries [1]. However, adulteration of PDE-5 MetID program with database function. A multi-event inhibitors and their analogues are found in dietary method was used to acquire HR-TICs with enhanced supplements and health products in recent years [1-3]. The sensitivity. An un-targeted screening approach was adulteration is illegal and dangerous for consumers established using a concerned compound database of because none of the analogues is approved ofcially for thirty-two PDE-5 inhibitors and their analogues and applied medical use. Analytical methods based on HPLC and to ve health supplements obtained from local market.
    [Show full text]
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1
    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
    [Show full text]